i think neurocrine systems wuss one, edge wise, and viridian.ere are not too many people watching right now who know anything about those companies. so i invite you to tell us. >> absolutely. let's start with neurocrine. this is a larger cap name with a product ingressa. the carta diskinesia market has only diagnosed about 35% of the patients but ingressa already has a $2 billion run. and beyond that, they are marketing another product that should be in the market by 2025. so a lot to like here with neurocrine, a focus in the neurology and endocrine areas right now. >> and the other, viridian? >> starting with viridian, this is a company focused more on immunology and information space. their asset is going after thyroid eye disease. you may have heard of that from it peza. it is an exciting year. they will have a trial leadout in the middle of this year and later this year in two forms of thyroid eye disease. a lot going on there. and edge wise, the last name on the roundup, this is another company focused in muscular dystrophy. and we saw edge